Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

NCT03897491 is registered in ClinicalTrials.gov with photonamic GmbH & Co. KG as lead sponsor.

NCT NCT03897491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03897491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
Lead sponsor
photonamic GmbH & Co. KG
Phase
Phase 2
Overall status
Terminated
Start date
September 3, 2021
Completion date
April 8, 2026
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma